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Abstract: To investigate the incidence and risk factors of retinopathy of
prematurity (ROP) andType 1ROP in extremely pretermChinese infants.
A retrospective review of medical records was performed of all ext-
remely preterm neonates (gestational age, GA 28 weeks) screened for
ROP from2007 to2012at anophthalmologycentre inHongKong.Thirty-
threematernal and neonatal covariateswere analyzedusing univariate and
multivariate regression analyses for both ROP and Type 1 ROP.
The mean gestational age (GA) was 26.4 1.3 weeks and the birth
weight (BW) was 855.0 199.0 g. The incidence of ROP development
was 60.7% and 16.2% for Type 1 ROP. On univariate analysis, 6 risk
factors were identified for ROP development including: lighter BW;
lower GA; postnatal hypotension; inotrope use; surfactant use; and
invasive mechanical ventilation (all P 0.01). On multivariate analysis,
neonatal congenital heart disease and greater GA were protective factors
for ROP development (P 0.04). On the other hand, 4 risk factors were
associated with Type 1 ROP development in univariate analysis, includ-
ing: lower GA, lighter BW, multiple pregnancies, and invasive mech-
anical ventilation (all P 0.02); while there was no significant risk
factors on multivariate analysis.
A lighter BW and lower GA were the only common independent risk
factors for both ROP and Type 1 ROP while neonatal congenital heart
disease and greater GA were the protective factors against ROP.
(Medicine 93(28):e314)
Abbreviations: ANS = antenatal steroid, BW = birth weight,
CRYO-ROP = Cryotherapy for retinopathy of prematurity, ETROP
= early treatment for retinopathy of prematurity, GA = gestational
age, GDM = gestational diabetes mellitus, IVF = in vitro
fertilization, IVH = intraventricular hemorrhage, NEC =
necrotizing enterocolitis, NICU = neonatal intensive care units,
NNJ = neonatal jaundice phototherapy, NSAID = non-steroidal
anti-inflammatory agents, PDA = patent ductus arteriosus, PET =FRCSEd, Victor T hthHK,
an Y.H. Wong, FCOphthHK
INTRODUCTION
R etinopathy of prematurity (ROP) is a vasoproliferativedisease of the developing retina, most vulnerable to low
birth weight, pre-term neonates.1 ROP has emerged as one of
the leading causes of childhood blindness in developed nations.2
With advancement and modernization in neonatal intensive care
units, the increased survival rates for extremely preterm infants
(gestational age, GA 28 weeks), has increased over the past
decades.3–10 The aim of this study was to determine the
incidence and risk factors of ROP development and Type 1
ROP in extremely preterm Chinese infants.
PATIENTS AND METHODS
The study was approved by the Institutional Review Board
of the Hospital Authority of Hong Kong. The study was
conducted in accordance with the Declaration of Helsinki
and no patient personal data were disclosed in the study. The
authors declare no financial or proprietary interests.
This was a retrospective study conducted at pediatric
ophthalmic unit of Caritas Medical Centre, Hong Kong Special
Administrative Region, China, which provides pediatric oph-
thalmological service to 2 local Neonatal Intensive Care Units
(NICU) at Princess Margaret Hospital and Kwong Wah Hospi-
tal, for a population of 1.8 million.
Medical records for consecutive subjects screened for ROP
between the period of January 2007 and December 2012 were
retrieved using the Clinical Data Record System of the Hospital
Authority of Hong Kong.
ROP Screening Criterion
All preterm babies admitted to these 2 NICU’s with a birth
weight (BW) 1500 g and/or gestational age (GA) 32 weeks
were referred to a pediatric ophthalmologist for evaluation. All
eligible preterms were examined according to the screening
protocol recommended by the Royal College of Ophthalmol-
ogists and United Kingdom-ROP (UK-ROP) guidelines.11,12
Subjects were first screened at 4 to 8 weeks of postnatal age
(30 week GA) and were examined weekly to bi-weekly, until
retinal vascularization reached zone 3 or feature of established
ROP regression.12 As all pre-terms were in-patients, a close
liaison between the attending neonatologist and pediatric
ophthalmologist prevented any missed cases. Treatment was
diode laser was implemented when the disease progressed to
Type 1 ROP as per the early treatment for retinopathy of
prematurity (ETROP) study.13 The staging of ROPwas recorded
according to the revised International Classification of ROP,
including the extent, zone, and presence or absence of ‘‘plus’’
disease.14 Type 1 ROP was defined as high risk pre-threshold
ROP, with either one of the following features: (i) Zone I, anyisease (2 quadrant involvement as per
Zone I, Stage 3 ROPwith or without plus
I, stage 2 or 3 ROP with plus disease.13
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neoAll examinations were performed by 3 experienced
pediatric ophthalmologists (SKY, TYT, CYC). Each infant
was screened by an indirect ophthalmoscope using a 30-dioptre
(D) lens after full pharmacological pupil dilatation with tropi-
camide 0.5% and phenylephrine 1% eye drops. A lid speculum
with scleral indentation after topical anesthesia (amethocaine)
was routinely used. All screening was performed under oxygen
saturation monitoring and the screening was temporarily with-
Yau et alheld in case of desaturations.
The inclusion criteria included all extremely preterm sub-
jects withGA 28weeks that receivedROP screening. In infants
TABLE 1. Univariate and Multivariate Analysis of Maternal and N
Infants
Covariates
Univariate Logistic Analy
P-Value
Coefficient
Estimates
Odds
Ratio
Gender 0.73 0.14 0.87
Gestational age <0.001#,
 1.08 0.34
Birth weight <0.001#,

0.00 1.00
Multiple pregnancies 0.78 0.15 1.16
Pre-eclampsia 0.26 0.66 0.51
Gestational diabetes mellitus 0.34 0.88 0.42
In vitro fertilization 0.54 0.51 1.67
Postnatal hypotension <0.001#,

1.30 3.66
Inotrope use 0.03#,

0.90 2.47
Antenatal steroid use 0.39 0.40 0.67
Apgar score 1min 0.04#,
 0.21 0.81
Apgar score 5min 0.29 0.11 0.89
Apgar score 10min 0.55 0.09 0.92
Respiratory distress
syndrome
0.76 0.44 1.56
Bronchopulmonary dysplasia 0.11 0.62 1.86
Surfactant use <0.001#,

1.49 4.42
Invasive mechanical
ventilation
0.02#,

1.23 3.40
Oxygen supplement <0.001

NA NA
Mean oxygen
concentration (%)
<0.001

0.00 1.00
Congenital heart disease <0.001

0.00 1.00
Patent ductus arteriosus <0.001

0.00 1.00
NSAID use <0.001

0.00 1.00
Anemia <0.001

0.00 1.00
Thrombocytopenia <0.001

0.00 1.00
Blood transfusion <0.001

0.00 1.00
Intraventricular
hemorrhage
<0.001

0.00 1.00
Nectrotizing colitis <0.001

0.00 1.00
Neonatal jaundice <0.001

0.00 1.00
Phototherapy <0.001

0.00 1.00
Total parental nutrition <0.001

0.00 1.00
Hypoglycemia <0.001

0.00 1.00
Sepsis <0.001

0.00 1.00
Meningitis <0.001

0.00 1.00

Statistically significant.
# Clinically significant.
2 | www.md-journal.comwhere the diagnosis of ROP could neither be confirmed nor ruled
out either due to premature death or insufficient clinical infor-
mation were excluded. The primary outcomemeasures included:
the severity of ROP (the extent, zone, and presence or absence of
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0.40
0.21
0.99
0.40
0.16
0.05
0.34
1.66
1.10
0.25
0.65
0.71
0.67
0.06
0.88
1.69
1.19
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00s’’ disease) as well as the 33 risk factors (both maternal and
natal) for the development of ROP as follows:
Antenatal maternal risk factors: (Table 1)Maternal diseases: pre-eclampsia (PET), gestational dia-
betes mellitus (GDM), order of pregnancy (singleton or
multiple gestations).
l Covariates for ROP Development in Extremely Preterm
Multivariate Logistic Analysis
95%
nfidence
terval P-Value
Coefficient
Estimates
Odds
Ratio
95%
Confidence
Interval
1.90 Excluded from multivariate logistic analysis
0.51 <0.001#,
 0.95 0.39 0.22 0.64
1.00 0.63 0.00 1.00 1.00 1.00
3.77 Excluded from multivariate logistic analysis
1.65 Excluded from multivariate logistic analysis
2.60 Excluded from multivariate logistic analysis
12.00 Excluded from multivariate logistic analysis
8.45 0.28 0.57 1.77 0.63 5.05
5.80 Excluded from multivariate logistic analysis
1.67 Excluded from multivariate logistic analysis
0.99 Excluded from multivariate logistic analysis
1.10 Excluded from multivariate logistic analysis
1.22 Excluded from multivariate logistic analysis
40.00 Excluded from multivariate logistic analysis
4.02 Excluded from multivariate logistic analysis
12.64 0.12 0.93 2.54 0.81 8.50
10.62 Excluded from multivariate logistic analysis
1.00 Excluded from multivariate logistic analysis
1.00 Excluded from multivariate logistic analysis
1.00 0.04#,
 1.20 0.30 0.09 0.92
1.00 Excluded from multivariate logistic analysis
1.00 0.42 0.48 1.61 0.51 5.34
1.00 Excluded from multivariate logistic analysis
1.00 Excluded from multivariate logistic analysis
1.00 Excluded from multivariate logistic analysis
1.00 Excluded from multivariate logistic analysis
1.00 Excluded from multivariate logistic analysis
1.00 Excluded from multivariate logistic analysis
1.00 Excluded from multivariate logistic analysis
1.00 Excluded from multivariate logistic analysis
1.00 Excluded from multivariate logistic analysis
1.00 0.19 0.64 1.90 0.73 5.06
1.00 Excluded from multivariate logistic analysis
# 2014 Lippincott Williams & Wilkins
ROP in Extremely Preterm Chinese InfantsMed


we
trip
(60
# 2icine  Volume 93, Number 28, December 2014January 2007 to December 2012 In vitro fertilization (IVF).
 Use of antenatal steroid (ANS).612 infants screenedExtreme premature infants ≤28 wks GA
139Neonatal risk factors: (Table 1)
Demographic information (GA, BW, gender).
Apgar scores at 1, 5, and 10minutes.
Postnatal interventions: surfactant administration; mechan-
ical ventilation; use of supplementary oxygen; maintenance
supplementary oxygen concentration (mean oxygen con-22 excluded:
5 died, 4 loss of clinical data;
13 randomly exclude from multiple
pregnancy
117  included for data analysis
ROP diagnosed
71
No ROP
46
Type 1 ROP
19
Less than type1 ROP
52centration); use of non-steroidal anti-inflammatory agents
(NSAID) for patent ductus arteriosus (PDA) closure; blood
transfusion; and total parental nutrition (TPN).
 Neonatal diseases: respiratory distress syndrome (RDS);
bronchopulmonary dysplasia; hypotension; congenital heart
disease; PDA; anemia (defined as hemoglobin <110 g/L,
hematocrit <25%); thrombocytopenia; neonatal jaundice
(NNJ), phototherapy, intraventricular hemorrhage (IVH);
necrotizing enterocolitis (NEC); hypoglycemia; sepsis
(culture positive or use antibiotics for more than 7 days);
and meningitis.
Statistics
To eliminate the duplication of data from multiple preg-
nancies, only 1 subject in cases of multiple pregnancies, were
randomized (by card shuffling) for inclusion in the statistical
analysis. The correlation of the 33 covariates with the devel-
opment of ROP and Type 1 ROP were analyzed separately using
univariate and multiple logistic regression analyses. Univariate
correlation between the covariates and ROP development was
analyzed using logistic regression and linear regression for
categorical and continuous variables, respectively. For multiple
logistic regressions, covariates with zero estimate of coeffi-
cients were excluded. Variable selection by elastic net method
was used to select out redundant covariates to address the high
collinearity of the sample. Correlations were expressed in
coefficients and odds ratio (OR) and a P-value less than 0.05
was considered as statistically significant. All means were
expressed as mean standard deviation.
RESULTS
During the study period, a total of 612 preterm infants were
screened. Out of the 612 infants that received screening, 139
(22.7%) met the inclusion criteria of extremely preterm
(GA 28 weeks). The diagnosis of ROP could neither be
established nor ruled out in 9 (6.5%) subjects since 5 (3.6%)
were deceased and 4 (2.9%) had insufficient clinical infor-
mation. Twenty-six infants belonged to multiple pregnancies
and 1 infant from each multiple pregnancy was randomized for
inclusion in the study. The remaining 117 eligible extreme
preterm infants were included for analysis (Figure 1).
Demographics
Of the 117 infants included in the study, all were of
Chinese ethnicity. There were 76 male (65.0%) and 41 female
(35.0%) subjects. The mean GA at birth was 26.4 1.3 weeks
(range: 23.4–28.0 weeks) and the mean BW was
855.0 199.0 g (range: 445–1535 g). The majority (104/117)re singletons (88.9%), 12 were twins (10.3%), and 1 were
lets (0.9%). ROP in any stage developed in 71 infants
.7%) and Type 1 ROP developed in 19 infants (16.2%).
014 Lippincott Williams & WilkinsOut of 117 extremely preterm infants, 68 of them
had GA 27 weeks and the incidence of Type I ROP in infants
27 weeks was 27.9%. In our study, no infants with a BW
greater than 900 g and a GA more than 27 weeks developed
Type 1 ROP requiring treatment.
Risk Factor Analysis for ROP
Using univariate analysis, the following were significant
risk factors for ROP development: lighter BW; lower GA;
postnatal hypotension; inotrope use; surfactant use; lower
Apgar score at 1minute; and surfactant use (all P 0.02)
(Table 1).
The following covariates were also significantly associated
with ROP on a statistical level (all P 0.01) but as the
OR¼ 1.00, there was no clinical significance of these covariates
as predictors of ROP: oxygen supplement; higher mean oxygen
concentration; congenital heart disease; presence of PDA;
NSAID use; anemia; thrombocytopenia; blood transfusion;
IVH; NEC; NNJ; phototherapy; TPN; hypoglycemia; sepsis;
and meningitis.
Using multivariate logistic analysis, the presence of con-
genital heart disease and a greater GA were protective factors
FIGURE 1. Schematic diagram of the distribution of extremely
preterm infants.against ROP development (Table 1). All the congenital heart
diseases were non-cyanotic (ventricular septal defects or arterial
septal defects).
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TABLE 2. Univariate and Multivariate Analysis of Maternal and Natal Covariates for Type 1 ROP Development in Extremely
Preterm Infants
Covariates
Univariate Logistic Analysis Multivariate Logistic Analysis
P-Value
Coefficient
Estimates
Odds
Ratio
95%
Confidence
Interval P-Value
Coefficient
Estimates
Odds
Ratio
95%
Confidence
Interval
Gender 0.37 0.49 0.62 0.19 1.76 1.00 30.18 0.00 0.00 Infinity
Gestational age <0.001#,
 1.46 0.23 0.11 0.42 1.00 74.78 0.00 0.00 Infinity
Birth weight <0.001#,
 0.01 0.99 0.99 1.00 1.00 0.27 0.76 0.00 Infinity
Multiple pregnancies 0.02#,

1.40 4.05 1.28 13.14 1.00 146.70 Infinity 0.00 Infinity
Pre-eclampsia 0.34 0.92 0.40 0.02 2.22 Excluded from multivariate logistic analysis
Gestational diabetes
mellitus
0.18 15.98 0.00 NA Infinity 1.00 85.33 Infinity 0.00 Infinity
In vitro fertilization 0.08 1.48 4.41 0.81 21.87 1.00 47.28 Infinity 0.00 Infinity
Postnatal hypotension 0.20 0.65 1.91 0.71 5.34 1.00 344.30 0.00 0.00 Infinity
Inotrope use 0.10 0.83 2.29 0.84 6.32 1.00 265.30 Infinity 0.00 Infinity
Antenatal steroid use 0.97 0.02 1.02 0.33 3.87 Excluded from multivariate logistic analysis
Apgar score 1min 0.13 0.19 0.82 0.64 1.06 Excluded from multivariate logistic analysis
Apgar score 5min 0.36 0.12 0.89 0.69 1.16 Excluded from multivariate logistic analysis
Apgar score 10min 0.24 0.20 0.82 0.59 1.16 1.00 30.64 0.00 0.00 Infinity
Respiratory distress
syndrome
0.40 14.95 3,097,665.00 0.00 NA Excluded from multivariate logistic analysis
Bronchopulmonary
dysplasia
0.10 0.83 2.29 0.85 6.61 Excluded from multivariate logistic analysis
Surfactant use 0.06 1.59 4.91 0.93 90.84 Excluded from multivariate logistic analysis
Invasive mechanical
ventilation
0.01#,

17.12 27,127,490.00 0.00 NA 1.00 105.40 Infinity 0.00 Infinity
Oxygen supplement <0.001

NA NA 1.00 1.00 Excluded from multivariate logistic analysis
Mean oxygen
concentration (%)
<0.001

0.00 1.00 1.00 1.00 Excluded from multivariate logistic analysis
Congenital heart disease <0.001

0.00 1.00 1.00 1.00 1.00 19.28 235,515,500.00 0.00 Infinity
Patent ductus arteriosus <0.001

0.00 1.00 1.00 1.00 Excluded from multivariate logistic analysis
NSAID use <0.001

0.00 1.00 1.00 1.00 1.00 117.00 Infinity 0.00 Infinity
Anemia <0.001

0.00 1.00 1.00 1.00 1.00 343.60 0.00 0.00 Infinity
Thrombocytopenia <0.001

0.00 1.00 1.00 1.00 1.00 83.88 0.00 0.00 Infinity
Blood transfusion <0.001

0.00 1.00 1.00 1.00 1.00 345.30 Infinity 0.00 Infinity
Intraventricular
hemorrhage
<0.001

0.00 1.00 1.00 1.00 1.00 144.70 0.00 0.00 Infinity
Nectrotizing colitis <0.001

0.00 1.00 1.00 1.00 Excluded from multivariate logistic analysis
Neonatal jaundice <0.001

0.00 1.00 1.00 1.00 1.00 109.20 0.00 0.00 Infinity
Phototherapy <0.001

0.00 1.00 1.00 1.00 NA NA NA NA NA
Total parental nutrition <0.001

0.00 1.00 1.00 1.00 Excluded from multivariate logistic analysis
Hypoglycemia <0.001

0.00 1.00 1.00 1.00 1.00 119.10 Infinity 0.00 Infinity
Sepsis <0.001

0.00 1.00 1.00 1.00 1.00 156.50 Infinity 0.00 Infinity
Meningitis <0.001

0.00 1.00 1.00 1.00 1.00 257.30 Infinity 0.00 Infinity

Yau et al Medicine  Volume 93, Number 28, December 2014Risk Factor Analysis for Type 1 ROP
Using univariate analysis, the following were significant
risk factors for Type 1 ROP: a lighter BW; lower GA; multiple
pregnancies; and use of invasive mechanical ventilation
(P 0.02) (Table 2).
The following covariates were also significantly associated
with Type 1 ROP on a statistical level (all P 0.01) but as the
Statistically significant.
# Clinically significant.OR¼ 1.00, there was no clinical significance of these covariates
as predictors of ROP: oxygen supplement; higher mean oxygen
concentration; congenital heart disease; presence of PDA;
4 | www.md-journal.comNSAID use; anemia; thrombocytopenia; blood transfusion;
IVH; NEC; NNJ; phototherapy; TPN; hypoglycemia; sepsis;
and meningitis.
When using multivariate analysis, none of the covariates
(neither risk nor protective factors) reached a level of statistical
significance (Table 2).DISCUSSION
In several population-based studies involving Caucasians,
a lower GA was associated with a higher incidence of severe
# 2014 Lippincott Williams & Wilkins
ROP.8–10 In a Norwegian population-study by Markestad et al,8
none of the infants with GA >25 weeks developed ROP
requiring treatment as compared to 33% in those born at 23
weeks. In another Sweden study by the EXPRESS Group, there
was a log-linear relationship between severe ROP and GA at
birth, whereby a larger GA was associated with a lower risk of
severe ROP.9,10 The overall incidence of Type 1 ROP with
GA 28 weeks was 16.2% in our study, which was comparable
to the reported incidence in the first BOOST trial that reported
incidences of 16% in the standard target oxygen-saturation
group and 8% for the high oxygen-saturation group.15 In the
BOOST-II study, the incidence was 10.6% in the lower target-
saturation group and 13.5% in the higher-target group.16
In Japan, the incidence is higher at 19.6%.17 The incidence
of ROP and severe ROP vary throughout the literatures, most
probably related to differences in standard of neonatal intensive
care and socioeconomic status of different geographical
regions, as well as changing of the supplementary oxygen
delivery guidelines throughout the years.15,16,18–22 The survival
rate of extremely preterm infants has increased over the years
following improvements in neonatal intensive care, resulting in
a greater number of preterm infants developing ROP.23 To the
best of our knowledge, this is one of the largest cohorts
reporting the incidence and risk factors of ROP in preterm
Hong Kong Chinese infants.
The frequency of ROP in any stage, among babies born
before the 27th week of gestation were reported to be 83.4% and
89.0% in the cryotherapy for retinopathy of prematurity
(CRYO-ROP) study24 and ETROP study,13 respectively. In
our study, the incidence of ROP in any stage among extremely
preterm infants 28 weeks was 60.7%, which was comparable
to the reported incidence in Canada (64.7%)7 but less than that
in Turkey (78.26%)25 and Japan (70.6%).17 The lower incidence
in our cohort when compared to the CYRO-ROP and ETROP
studies, may be attributed to the improvement of the neonatal
intensive care since their publication as well as the inclusion of
more mature infants (GA 28 weeks) in our study; only 58.1%
(68/117) of our infants had GA 27 weeks. On the other hand,
the Turkish study had the same inclusion criteria as our study,
thus, differences in incidence may primarily be due to differ-
ences in neonatal care.
In univariate analysis, a lower BW and a lower GA
increased the risk of both ROP and Type 1 ROP. This finding
was consistent with the result of an 18-year study in Australia4
and with other population studies published over the years.8–10
On multivariate analysis, GA but not BW was a consistent
predictor for ROP develop. This finding was inline with the
finding of Woo et al26 who reported that GA was a better
predictor of ROP than BW in preterm twin-pairs. On multi-
variate analysis, GA but not BW was a consistent predictor for
ROP develop. This finding was inline with the finding of Woo
et al who reported that GA was a better predictor of ROP than
BW in preterm twin-pairs. Similarly, Isaza and Arora reported
that premature infants with lower GA had a higher incidence of
Type 1 ROP and that no infants with a GA >26 weeks or BW
>1000 g developed Type 1 ROP.27 Likewise, in our study, no
infants with a GAmore than 27 weeks or with a BW greater than
900 g developed Type 1 ROP requiring treatment.
Mizoguchi et al28 reported a strong association of inotropes
use in management of postnatal hypotension with the develop-
Medicine  Volume 93, Number 28, December 2014ment of threshold ROP in preterm infants. In our study, inotrope
use was an independent risk factor for ROP development
(OR¼ 2.47 P¼ 0.03) but not for Type 1 ROP (P¼ 0.10).
# 2014 Lippincott Williams & WilkinsInvasive mechanical ventilation was an independent risk factor
for both ROP and Type 1 ROP (P 0.01) in our study.
There exist controversies about the association of multiple
gestation and ROP or threshold ROP. Bossi et al29 revealed that
preterm infants of multiple pregnancies carried a higher risk of
ROP while Shaffer et al24 found a higher risk of threshold ROP
in multiple-gestation infants when compared to singletons. On
the other hand, Shohat et al30 and Friling et al31 did not find such
association. In univariate analysis, we found that infants of
multiple gestations had a higher risk (OR¼ 4.05, P¼ 0.02) of
developing Type 1 ROP, requiring diode laser treatment, when
compared to singleton infants.
On multiple regression analysis, the presence of congenital
heart disease (OR¼ 0.09, P¼ 0.04) was significant protective
factor against ROP development and this observation was also
evident in a previous publication investigating extremely low
birth weight (1000 g) Chinese infants.32 Unfortunately, we do
not have a solid explanation for this observation as most
previously published literature have found a positive correlation
of congenital heart disease with ROP development.31,33,34 For
cyanotic heart diseases with right (non-oxygenated) to left
(oxygenated) shunts, the oxygen concentration may be lowered,
potentially explaining the protective mechanism against ROP.
However, in ours series, all the congenital heart diseases were
non-cyanotic (ventricular septal defects or arterial septal
defects), so the above theory cannot account for our obser-
vations. We can only postulate that in preterm infants born with
congenital heart disease, more vigilant monitoring and control
of oxygen may have offered a better optimization of the target
oxygen saturation, conferring an indirect protective mechanism
for ROP development.
Our study had its limitations. Firstly, the retrospective
nature of this study inevitable generates inconsistencies in data
although every effort was made to exclude subjects with
incomplete clinical data. Secondly, subjects were screened
by 3 pediatric ophthalmologists and minor inter-observer varia-
bility can exits but as all were trained to follow a strict ROP
screening guideline; digital photographic documentation was
not available at the time of the study; given the large population
requiring screening, it was the most optimal balance in terms of
providing clinical service and standardization for research.
Moreover, our study was mainly a hospital-based study rather
than a population-based study but our service coverage spans
over 2 NICU’s, involving more than 1.8 million people. Never-
theless, our study provided information on the incidence and
risk factors of ROP in an extremely preterm Chinese population
using the UK-ROP screening guidelines. This serves as a plat-
form for future multi-centre, prospective trials among Chinese
populations. The findings of this study were generated from a
population extremely preterm Chinese infants in Hong Kong
and may not be generalizeable to other populations of different
ethnicities, gestational ages, and health care practices.
In Chinese extremely preterm infants, a lighter BW and
lower GA were the only common independent risk factors for
both ROP and Type 1 ROP. Multiple pregnancies and invasive
mechanical ventilation were associated with the development of
the more aggressive Type 1 ROP on univariate analysis. Neo-
natal congenital heart disease and a greater GA were protective
factors against ROP.
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